Skip to main content
Skip to section navigation
Skip to footer
About Us
Company Overview
Management
Board of Directors
Pipeline
Pipeline Overview
Paxalisib
PD-L1 Protein Degrader
SETDB1 Inhibitor
EVT801
Clinical Trials
Posters & Publications
Technology
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Investors
Investors Overview
News & Events
Company Info
Financial Results
Stock Data
SEC Filings
Governance
ASX Delisting
Contact Us
ASX Announcements
Media Center
Media Center
Media Center Overview
News
Events
In The News
Video Gallery
ASX Announcements
Nov 15, 2023
Removal from Official List
Nov 14, 2023
Change in substantial holding
Nov 13, 2023
Suspension from Official List
Nov 8, 2023
Change in substantial holding
Nov 3, 2023
Notice of Annual General Meeting/Proxy Form
Nov 2, 2023
Preliminary update from ongoing Phase 2 Study of Paxalisib
Oct 31, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 31, 2023
Kazia announces short term unsecured Promissory Note
Oct 31, 2023
Proposed issue of securities - KZA
Oct 27, 2023
Kazia SEC Form 20-F
rss_feed
RSS
Page
1
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Page
10
…
Page
19
Next Page
arrow_forward
Select a page
Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19